



Twist Bioscience Appoints Erin Smith Senior Vice President, Government Affairs and Public Policy

July 23, 2020

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 23, 2020-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Erin Smith to the newly created position of senior vice president of government affairs and public policy.

"With the government and legislative landscape constantly shifting, we welcome Erin's prowess and ability to strategically navigate and amplify our messages with key constituencies at this pivotal time in our history," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Her demonstrated ability to build consensus and alliances will help to position Twist as a critical resource for government."

Erin brings demonstrated leadership in furthering industry agendas by working with key stakeholders and government officials. Previously, Erin led the expansion of a government affairs program at Gilead Sciences and before that, Erin led the creation of government affairs programs at other companies including DaVita Rx. Erin's tenure in government service began in recent Secretary of Energy and former Governor Rick Perry's Office as an advisor on health care policy and finance, focusing on the coordination of state and federal resources and policy. Erin serves as adjunct faculty at the University of Houston Law Center where she teaches courses on legislative strategy, government affairs and public policy. Erin earned her J.D. with honors from the University of Houston Law Center, her M.P.H. with honors from the University of Texas Health Science Center, and her B.A. with distinguished honors from Drew University.

"Twist's diversified business model provides incredible opportunity to leverage the momentum around the bioeconomy," said Smith. "I'm thrilled to join such an innovative and forward-thinking company and am eager to advance the understanding and impact of our pivotal DNA synthesis platform as it relates to synthetic biology, next-generation sequencing, biopharma and DNA data storage."

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including diagnostics, therapeutics, industrial chemicals, agriculture and academic research. For more information visit www.twistbioscience.com and www.twistbiopharma.com.

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk of breach of Twist's security measures, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Quarterly Report on Form 10-Q dated May 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200723005277/en/): <https://www.businesswire.com/news/home/20200723005277/en/>

Investor Contact:

Argot Partners

Maeve Conneighton

212-600-1902

maeve@argotpartners.com

Media Contact:

Angela Bitting
925- 202-6211
media@twistbioscience.com

Source: Twist Bioscience Corporation